Edding Genor Group Holdings Limited (HKG:6998)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.040
+0.010 (0.33%)
Feb 13, 2026, 4:08 PM HKT
Market Cap6.09B
Revenue (ttm)n/a +1,448.1%
Net Incomen/a
EPSn/a
Shares Out2.00B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,662,000
Average Volume1,925,345
Open3.030
Previous Close3.030
Day's Range3.010 - 3.110
52-Week Range1.640 - 5.600
Beta0.95
RSI62.84
Earnings DateMar 27, 2026

About HKG:6998

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in clinical development for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are in preclinical and early clinical stages. It also provides Van... [Read more]

Sector Healthcare
Founded 2001
Employees 17
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6998
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements